As described in Our Technology, Research and Development, and Drug Discovery sections, Mito Biopharma has advanced its synthetic program to several different classes of lead compounds with distinct PD properties that mimic the actions of UCP1 and UCP2/3.

Currently, Mito Biopharma has elected IND lead compounds for NASH and type 2 diabetes indications. In addition, potential lead compounds for metastatic liver cancer, AML/ALL, are being validated. Going forward, we anticipate exploring other therapeutic applications consistent with the core platform technology.